Work

Supplementary Figure Legend from A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies

Year: 2023
Type: supplementary-materials
Abstract: PDF file - 45KB
Language: English
Field: Medicine
Open Access status: gold
OpenAlex ID: W4362395068
Cites:
Cited by:
Related to: 10